In vivo β-adrenergic blockade by propranolol prevents isoproterenol-induced polycystic ovary in adult rats.
Increasing evidence in animal models and in humans shows that sympathetic nerve activity controls ovarian androgen biosynthesis and follicular development. Thus, sympathetic nerve activity participates in the follicular development and the hyperandrogenism characteristics of polycystic ovary syndrome, which is the most prevalent ovarian pathology in women during their reproductive years. In this study, we mimic sympathetic nerve activity in the rat via "in vivo" stimulation with isoproterenol (ISO), a β-adrenergic receptor agonist, and test for the development of the polycystic ovary condition. We also determine whether this effect can be reversed by the administration of propranolol (PROP), a β-adrenergic receptor antagonist. Rats were treated for 10 days with 125 μg/kg ISO or with ISO plus 5 mg/kg PROP. The ovaries were examined 1 day or 30 days following drug treatment. While ISO was present, the ovaries had an increased capacity to secrete androgens; ISO + PROP reversed this effect on androgen secretory activity. 30 days after treatment, androstenedione secretion reverted to normal levels, but an increase in the intra-ovarian nerve growth factor (NGF) concentration and luteinizing hormone (LH) plasma levels was detected. ISO treatment resulted in follicular development characterized by an increased number of pre-cystic and cystic ovarian follicles; this was reversed in the ISO + PROP group. The lack of change in the plasma levels of progesterone, androstenedione, testosterone, or estradiol and the increased LH plasma levels strongly suggests a local intra-ovarian effect of ISO indicating that β-adrenergic stimulation is a definitive component in the rat polycystic ovary condition.
Laboratory of Neurobiochemistry, Universidad de Chile, Independencia, Santiago, Chile.
S L
SL
Luna
S
S
Neuman
J
J
Aguilera
D I
DI
Brown
H E
HE
Lara
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007545:Isoproterenol / Q000009:adverse effects; D007986:Luteinizing Hormone / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D011433:Propranolol / Q000008:administration & dosage*; D051381:Rats; D011943:Receptors, Adrenergic, beta / Q000378:metabolism
D000319:Adrenergic beta-Antagonists; D011943:Receptors, Adrenergic, beta; D007986:Luteinizing Hormone; D011433:Propranolol; D007545:Isoproterenol